Journal
NEUROIMAGE-CLINICAL
Volume 36, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.nicl.2022.103224
Keywords
MDD; Structural MRI; Prediction; Treatment response; Remission; SSRI
Categories
Funding
- Innovation Fund Denmark [4108-00004B]
- Lundbeck Foundation [R279-2018-1145]
- Lundbeck Foundation
Ask authors/readers for more resources
This study evaluated the performance of pretreatment structural brain magnetic resonance imaging measures in predicting the outcome of drug treatment for major depressive disorders. The results suggest that these measures can predict treatment response but not remission, and they do not generalize to an independent cohort.
Brain morphology has been suggested to be predictive of drug treatment outcome in major depressive disorders (MDD). The current study aims at evaluating the performance of pretreatment structural brain magnetic resonance imaging (MRI) measures in predicting the outcome of a drug treatment of MDD in a large single-site cohort, and, importantly, to assess the generalizability of these findings in an independent cohort. The random forest, boosted trees, support vector machines and elastic net classifiers were evaluated in predicting treatment response and remission following an eight week drug treatment of MDD using structural brain measures derived with FastSurfer (FreeSurfer). Models were trained and tested within a nested cross-validation framework using the NeuroPharm dataset (n = 79, treatment: escitalopram); their generalizability was assessed using an independent clinical dataset, EMBARC (n = 64, treatment: sertraline). Prediction of antide-pressant treatment response in the Neuropharm cohort was statistically significant for the random forest (p = 0.048), whereas none of the models could significantly predict remission. Furthermore, none of the models trained using the entire NeuroPharm dataset could significantly predict treatment outcome in the EMBARC dataset. Although our primary findings in the NeuroPharm cohort support some, but limited value in using pretreatment structural brain MRI to predict drug treatment outcome in MDD, the models did not generalize to an independent cohort suggesting limited clinical applicability. This study emphasizes the importance of assessing model generalizability for establishing clinical utility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available